{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu F"],"funding":["Natural Science Foundation of Hubei Province","Fundamental Research Funds for the Central Universities","National Natural Science Foundation of China"],"pagination":["118"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10170830"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(1)"],"pubmed_abstract":["<h4>Background</h4>The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can only slightly extend survival. How to improve RT/TMZ efficacy remains a major challenge in clinic.<h4>Methods</h4>Syngeneic G422<sup>TN</sup>-GBM model mice were subject to RT/TMZ, surgery, piperlongumine (PL), αPD1, glutathione. Metabolomics or transcriptomics data from G422<sup>TN</sup>-GBM and human GBM were used for gene enrichment analysis and estimation of ROS generation/scavenging balance, oxidative stress damage, inflammation and immune cell infiltration. Overall survival, bioluminescent ima"],"journal":["Journal of experimental & clinical cancer research : CR"],"pubmed_title":["Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8<sup>+</sup>-T cell immunity."],"pmcid":["PMC10170830"],"funding_grant_id":["81972362","2022CFB428","82173197","2021GCRC073","81873854","81974468"],"pubmed_authors":["Zhang TT","Yin SL","Zhou Q","Peng JY","Jiang HF","Wu JX","Chen XQ","Cao X","Pan F","Miao C","Xu SJ","He X","Gao PP","Liu F","Xu XH"],"additional_accession":[]},"is_claimable":false,"name":"Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8<sup>+</sup>-T cell immunity.","description":"<h4>Background</h4>The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can only slightly extend survival. How to improve RT/TMZ efficacy remains a major challenge in clinic.<h4>Methods</h4>Syngeneic G422<sup>TN</sup>-GBM model mice were subject to RT/TMZ, surgery, piperlongumine (PL), αPD1, glutathione. Metabolomics or transcriptomics data from G422<sup>TN</sup>-GBM and human GBM were used for gene enrichment analysis and estimation of ROS generation/scavenging balance, oxidative stress damage, inflammation and immune cell infiltration. Overall survival, bioluminescent ima","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-22T14:42:09.057Z","creation":"2025-04-06T01:06:17.496Z"},"accession":"S-EPMC10170830","cross_references":{"pubmed":["37161450"],"doi":["10.1186/s13046-023-02686-1"]}}